Teleflex (TFX) Stock News

Teleflex Incorporated (NYSE: TFX) announced that three clinical studies on its Barrigel™ rectal spacer will be presented at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. The studies focus on the safety and efficacy of Barrigel™, the first commercial hyaluronic acid rectal spacer designed to protect the rectum during prostate cancer radiation therapy.

Key presentations include:

• Impact of Hyaluronic Acid Rectal Spacer Quality Score on rectal dosimetry and toxicity outcomes
• Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol
• Hyaluronic Acid Rectal Spacer use in locally recurrent prostate cancer patients

Teleflex will also host an educational symposium on 'The Science of Personalized Spacing' and showcase the Barrigel™ procedure at their booth during the event.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has chosen o9's AI-powered platform to enhance its end-to-end integrated business planning and supply chain management capabilities. The partnership includes o9's Demand Planning, Supply Planning, and Integrated Business Planning (IBP) technologies.

Teleflex, headquartered in Wayne, Pennsylvania, offers a diverse portfolio of solutions in anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company aims to improve the health and quality of people's lives and become the most trusted partner in healthcare.

David Clarke, Vice President of Demand Fulfilment at Teleflex, expressed confidence in o9's ability to handle their complex supply chain requirements and help achieve strategic objectives. o9's platform is expected to enhance supply chain efficiency, optimize inventory, and empower Teleflex's workforce through improved processes and technology.

Teleflex (NYSE: TFX) announced that its Chairman, President and CEO, Liam Kelly, will be speaking at the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Friday, September 6, 2024, at 7:45 a.m. (ET) and will take place at the Marriott Marquis New York.

Investors and interested parties can access a live audio webcast of the conference presentation through the investor section of the Teleflex website. This presentation offers an opportunity for stakeholders to gain insights into Teleflex's current position and future strategies in the healthcare industry.

Teleflex Incorporated (NYSE: TFX) announced the publication of a retrospective analysis comparing the Titan SGS™ Stapler with traditional multi-fire staplers in laparoscopic sleeve gastrectomy (LSG). The study, conducted at an MBSAQIP-accredited facility, involved 807 patients using the Titan SGS™ Stapler and 3,829 patients using multi-fire staplers.

Key findings include:

• 8-minute reduction in median operative time with Titan SGS™
• Higher likelihood of 24-hour discharge (89.6% vs 65.0%)
• Fewer 30-day readmissions (1.7% vs 4.5%)
• No leaks, strictures, or post-operative interventions reported with Titan SGS™

The study suggests that the Titan SGS™ Stapler may enhance safety and effectiveness in LSG procedures, benefiting patients and healthcare providers.

Teleflex (NYSE: TFX) has announced a quarterly cash dividend of $0.34 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 15, 2024. This announcement demonstrates Teleflex's commitment to providing regular returns to its shareholders and maintaining its dividend policy. The declaration of a dividend can be seen as a positive signal of the company's financial health and confidence in its future prospects.

Teleflex (NYSE: TFX) released its Q2 2024 financial results with GAAP revenue at $749.7 million, a 0.9% YoY increase. Adjusted revenue, excluding Italian payback measures, rose 2.7% to $763.5 million, up 3.4% on a constant currency basis.

GAAP diluted EPS from continuing operations decreased to $1.69, down from $2.35 in the prior year. Adjusted diluted EPS remained steady at $3.42.

Teleflex has raised its 2024 GAAP revenue growth guidance to 3.40%-4.40% and adjusted constant currency revenue growth to 4.25%-5.25%. However, it lowered its GAAP EPS guidance to $6.43-$6.83 while increasing adjusted EPS guidance to $13.80-$14.20.

The company announced a $500 million share repurchase, including a $200 million accelerated buyback. Segment highlights include a 5.6% rise in OEM revenue and a 13.1% increase in Interventional revenue. Cash reserves stand at $238.6 million, up from $222.8 million at the end of 2023.

Teleflex Incorporated (NYSE: TFX) has received FDA 510(k) clearance for its Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon. This innovative device features a unique helical balloon that allows for continuous coronary blood flow during prolonged inflations. The Ringer™ PBC is indicated for balloon dilatation of coronary artery or bypass graft stenoses where distal blood perfusion is desired during inflation.

The Ringer PTCA Clinical Study showed that inflation of the Ringer™ PBC for 60 seconds or more was well-tolerated in most patients vulnerable to procedural ischemia. Teleflex plans a market release in August 2024, marking a significant advancement in interventional cardiology and demonstrating the company's commitment to addressing unmet clinical needs.

Teleflex Incorporated (NYSE: TFX) has secured two group purchasing agreements with Premier, Inc., effective July 1, 2024. These agreements, including the Premier National Hemostasis Products and SURPASS® Hemostasis Products agreements, offer Premier members special pricing on Teleflex's hemostatic portfolio. The SURPASS® program aims to achieve best-in-market pricing through aggregated purchasing and standardization.

Teleflex's QuikClot™ Hemostatic Dressings and Devices, which control bleeding faster than standard methods, are now available to Premier members. The portfolio includes products for various hospital departments. The agreements also cover other Teleflex hemostasis products, providing options for different bleeding scenarios in Interventional Cardiology and Radiology.

Teleflex Incorporated (NYSE: TFX) has announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit. Located in Research Triangle, North Carolina, TCAP is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. The center aims to be a resource for patients, physicians, and healthcare organizations through education and partnerships with infection prevention professionals.

TCAP recently sponsored an educational webinar on healthcare-acquired infections, specifically central line-associated bloodstream infections (CLABSI). Teleflex's Arrow™ Brand of Vascular Access Products offers a comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against various pathogens. The company also provides Arrow™ Maximal Barrier Kitting options to protect patients and improve procedural efficiency for clinicians.